BRPI0922220B8 - uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos - Google Patents

uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos

Info

Publication number
BRPI0922220B8
BRPI0922220B8 BRPI0922220A BRPI0922220A BRPI0922220B8 BR PI0922220 B8 BRPI0922220 B8 BR PI0922220B8 BR PI0922220 A BRPI0922220 A BR PI0922220A BR PI0922220 A BRPI0922220 A BR PI0922220A BR PI0922220 B8 BRPI0922220 B8 BR PI0922220B8
Authority
BR
Brazil
Prior art keywords
compounds
combination
pharmaceutical composition
antibacterial compounds
infections
Prior art date
Application number
BRPI0922220A
Other languages
English (en)
Portuguese (pt)
Inventor
Geoffrey Roach Alan
Richard Dorgan Colin
Xavier Wilson Francis
Michael Wynne Graham
De Moor Olivier
James Davis Paul
David Johnson Peter
Storer Richard
Vickers Richard
Original Assignee
Summit Oxford Ltd
Summit Corp Plc
Summit Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Oxford Ltd, Summit Corp Plc, Summit Therapeutics Plc filed Critical Summit Oxford Ltd
Priority to BR122020013025-3A priority Critical patent/BR122020013025B1/pt
Publication of BRPI0922220A2 publication Critical patent/BRPI0922220A2/pt
Publication of BRPI0922220A8 publication Critical patent/BRPI0922220A8/pt
Publication of BRPI0922220B1 publication Critical patent/BRPI0922220B1/pt
Publication of BRPI0922220B8 publication Critical patent/BRPI0922220B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
BRPI0922220A 2008-12-02 2009-12-01 uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos BRPI0922220B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020013025-3A BR122020013025B1 (pt) 2008-12-02 2009-12-01 uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
GB0821913.1 2008-12-02
PCT/GB2009/002792 WO2010063996A2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (4)

Publication Number Publication Date
BRPI0922220A2 BRPI0922220A2 (pt) 2015-12-29
BRPI0922220A8 BRPI0922220A8 (pt) 2018-04-03
BRPI0922220B1 BRPI0922220B1 (pt) 2021-03-09
BRPI0922220B8 true BRPI0922220B8 (pt) 2021-05-25

Family

ID=40262471

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0922220A BRPI0922220B8 (pt) 2008-12-02 2009-12-01 uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR122020013025-3A BR122020013025B1 (pt) 2008-12-02 2009-12-01 uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020013025-3A BR122020013025B1 (pt) 2008-12-02 2009-12-01 uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos

Country Status (27)

Country Link
US (3) US8975416B2 (OSRAM)
EP (3) EP3095783A1 (OSRAM)
JP (3) JP5665756B2 (OSRAM)
KR (1) KR101643435B1 (OSRAM)
CN (1) CN102227411B (OSRAM)
AU (1) AU2009323854B2 (OSRAM)
BR (2) BRPI0922220B8 (OSRAM)
CA (1) CA2744962C (OSRAM)
CY (2) CY1116383T1 (OSRAM)
DK (2) DK2907813T3 (OSRAM)
ES (2) ES2537059T3 (OSRAM)
GB (1) GB0821913D0 (OSRAM)
HR (2) HRP20150518T1 (OSRAM)
HU (1) HUE029151T2 (OSRAM)
IL (1) IL213325A (OSRAM)
LT (1) LT2907813T (OSRAM)
MX (1) MX2011005837A (OSRAM)
NZ (1) NZ593111A (OSRAM)
PL (2) PL2907813T3 (OSRAM)
PT (2) PT2907813T (OSRAM)
RS (1) RS54904B1 (OSRAM)
RU (1) RU2525915C2 (OSRAM)
SG (1) SG171939A1 (OSRAM)
SI (2) SI2907813T1 (OSRAM)
SM (2) SMT201500117B (OSRAM)
WO (1) WO2010063996A2 (OSRAM)
ZA (1) ZA201103751B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
SI2575968T1 (sl) 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
EP4233545A3 (en) 2012-11-23 2023-10-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1218559A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 抑制致病细菌生长的配方和方法
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
HK1220326A1 (zh) 2013-03-15 2017-05-05 Seres Therapeutics, Inc. 基於网络微生物组成和方法
PT3074027T (pt) 2013-11-25 2025-03-20 Nestle Sa Composições bacterianas sinérgicas e métodos de produção e utilização das mesmas
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
US11512068B2 (en) * 2017-10-05 2022-11-29 Sandoz Ag Process for the preparation of crystalline ridinilazole using acid addition salts
KR20200079292A (ko) 2017-10-30 2020-07-02 세레스 테라퓨틱스, 인코포레이티드 항생제 내성을 치료하기 위한 조성물 및 방법
US20220289705A1 (en) 2019-07-17 2022-09-15 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
KR20240011728A (ko) * 2021-05-24 2024-01-26 에임맥스 테라퓨틱스, 인코포레이티드 세균 감염의 치료 또는 예방을 위한 프리스티나마이신 ia 및 플로프리스틴 조합
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
KR20240035395A (ko) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 사용할 수 있는 요소 유도체
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (OSRAM) * 1974-04-30 1975-11-11
JPS50154250A (OSRAM) * 1974-05-31 1975-12-12
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
JPH09512831A (ja) * 1994-11-17 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー ジベンズイミダゾール誘導体
CN1164227A (zh) 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
AU2002218309A1 (en) 2000-11-27 2002-06-03 Ciba Specialty Chemicals Holding Inc. Substituted 5-aryl and 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole derivatives as uv absorbers
IL156031A0 (en) 2000-12-15 2003-12-23 Vertex Pharma Fused heterocyclic derivatives and pharmaceutical compositions containing the same
FR2819180B1 (fr) * 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
EP1524974A4 (en) 2001-05-04 2007-12-05 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CA2489128C (en) 2002-06-13 2012-01-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
WO2004035522A1 (ja) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
JP2006513162A (ja) 2002-11-01 2006-04-20 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用方法
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
DK1812440T3 (da) 2004-11-04 2011-01-31 Vertex Pharma Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
JP2008527032A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なチエノピロール
WO2008041966A2 (en) 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
JP2009514894A (ja) 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
MX2011008982A (es) 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
SG175001A1 (en) 2009-04-02 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
CA2763624A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
JP5744859B2 (ja) 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
SI2575968T1 (sl) 2010-06-01 2016-06-30 Summit Therapeutics Plc Spojine za zdravljenje bolezni, ki je povezana s clostridium difficile

Also Published As

Publication number Publication date
MX2011005837A (es) 2011-11-18
SI2373631T1 (sl) 2015-08-31
SI2907813T1 (sl) 2016-09-30
IL213325A (en) 2016-02-29
KR101643435B1 (ko) 2016-07-27
NZ593111A (en) 2013-05-31
ES2537059T3 (es) 2015-06-02
JP2012510458A (ja) 2012-05-10
EP2373631A2 (en) 2011-10-12
CN102227411A (zh) 2011-10-26
LT2907813T (lt) 2016-10-10
US20120020950A1 (en) 2012-01-26
CA2744962C (en) 2017-06-06
CY1116383T1 (el) 2017-02-08
PT2373631E (pt) 2015-06-09
JP2017048217A (ja) 2017-03-09
HK1208668A1 (en) 2016-03-11
BRPI0922220B1 (pt) 2021-03-09
CN102227411B (zh) 2015-10-14
HUE029151T2 (hu) 2017-02-28
ZA201103751B (en) 2014-10-29
GB0821913D0 (en) 2009-01-07
SMT201600259B (it) 2016-08-31
HK1162169A1 (en) 2012-08-24
RS54904B1 (sr) 2016-10-31
WO2010063996A3 (en) 2010-12-29
EP3095783A1 (en) 2016-11-23
HRP20160597T1 (hr) 2016-09-23
AU2009323854A1 (en) 2010-06-10
JP5665756B2 (ja) 2015-02-04
WO2010063996A2 (en) 2010-06-10
IL213325A0 (en) 2011-07-31
SG171939A1 (en) 2011-07-28
BRPI0922220A2 (pt) 2015-12-29
US20160184283A1 (en) 2016-06-30
BRPI0922220A8 (pt) 2018-04-03
KR20110093925A (ko) 2011-08-18
BR122020013025B1 (pt) 2021-05-18
US8975416B2 (en) 2015-03-10
US9314456B2 (en) 2016-04-19
DK2907813T3 (en) 2016-07-25
AU2009323854A2 (en) 2011-06-30
CY1117934T1 (el) 2017-05-17
HRP20150518T1 (hr) 2015-07-17
US20150150861A1 (en) 2015-06-04
SMT201500117B (it) 2015-07-09
RU2525915C2 (ru) 2014-08-20
ES2575908T3 (es) 2016-07-04
PT2907813T (pt) 2016-08-05
US9763925B2 (en) 2017-09-19
EP2907813B1 (en) 2016-04-27
JP2015078220A (ja) 2015-04-23
EP2373631B1 (en) 2015-02-25
PL2907813T3 (pl) 2016-09-30
CA2744962A1 (en) 2010-06-10
RU2011127165A (ru) 2013-01-10
DK2373631T3 (en) 2015-05-26
AU2009323854B2 (en) 2014-06-26
PL2373631T3 (pl) 2015-10-30
EP2907813A1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
BRPI0922220B8 (pt) uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201170772A1 (ru) Органические соединения
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
DK2164331T3 (da) Borholdige små molekyler
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BR112014022214A2 (pt) fenólicos antibacterianos
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados
BR112013024965A2 (pt) composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX367309B (es) Nuevos compuestos antibacterianos.
EA201490436A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные гомопиперидинилом
BRPI0908569B8 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica
EA201100754A1 (ru) [4-(1-аминоэтил)циклогексил]метиламины в качестве антибактериальных средств
MX363480B (es) Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi.
MX357352B (es) Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico.
EA201270817A1 (ru) Соединения, обладающие антибактериальной активностью в отношении clostridium
EA200901059A1 (ru) Макролиды на основе эритромицина
BR112015006243A2 (pt) agentes antibacterianos de fenicol
BR112012006250A2 (pt) composições e métodos para o tratamento de infecções bacterianas usando ceftaroline

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMMIT THERAPEUTICS PLC (GB)

B25A Requested transfer of rights approved

Owner name: SUMMIT (OXFORD) LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF